25 August 2025 in Journal of Neuroscience Nursing
BACKGROUND: Guidelines recommend the use of enteral nimodipine for 21 days after aneurysmal subarachnoid hemorrhage (aSAH). The recommended duration (21 d) and frequency of administration (every 4 h) may lead to noncompliance. Nurses play a critical role in medication administration, monitoring adverse reactions, and ensuring patient compliance with prescribed regimens. The aim of this study is to assess the degree of compliance with nimodipine use, causes of noncompliance and explore if adherence to nimodipine in clinical practice correlates with improved neurological outcomes as indicated by modified Rankin Scale (mRS) scores. METHODS: A retrospective study of consecutive aSAH admissions to a comprehensive stroke center over a 67-month period. Compliance was defined as receiving at least 80% of the recommended doses of nimodipine over 21 days. A chart review was performed to explore the reasons for noncompliance. We examined hospital disposition at discharge and 90-day mRS, adjusted for severity of aSAH. Compliance rates before and after a pharmacist-guided intervention were also examined. RESULTS: Among 141 patients, the overall compliance rate was just 30%. The leading reasons for missed doses included hypotension (68.1%) and patients being off the unit (56%). Compliance was not associated with improvement in 90-day mRS scores for low-grade aSAH ( P =0.3638) and high-grade aSAH ( P =0.227). After pharmacist-guided intervention, compliance improved from 18.2% to 43.8%. CONCLUSION: There is a high rate of noncompliance with nimodipine use in aSAH, but it did not significantly impact patient outcomes. Although pharmacist interventions improved compliance, full compliance remains challenging.
6 July 2026 in JCO Oncology Practice
PURPOSE: Ifosfamide is traditionally administered in an inpatient setting because of risks of neurotoxicity and hemorrhagic cystitis. To optimize quality of life while tackling the rising cancer care costs, organizations have been shifting chemotherapy administration to outpatient settings. This single-center, retrospective cohort study evaluated the safety and feasibility of administering ifosfamide-based chemotherapy regimens, MAI (mesna, doxorubicin, ifosfamide) and IE (ifosfamide, etoposide), in an outpatient service at a National Cancer Institute–designated Comprehensive Cancer Center. METHODS: This single-center study included patients age 18-60 years treated between 2018 and 2024. Fifty-eight patients receiving MAI or IE were managed either through the outpatient service or in the inpatient setting. Clinical outcomes, including readmissions, urgent care visits, toxicities, and treatment completion, were compared. Hospital resource utilization was assessed by estimating average inpatient bed days saved. RESULTS: The outpatient service saved an estimated 16.2 bed days per patient and 3.7 bed days per cycle. Clinical outcomes were comparable, with similar readmission (18.1% v 19.2%) and urgent care visit rates (5.5% v 4.8%), and no cases of hemorrhagic cystitis were reported. Grade ≥3 hematologic toxicities and treatment completion rates (>90%) were also similar across both arms. CONCLUSION: These findings demonstrate that ifosfamide-based regimens through a structured outpatient model are both safe and reducing hospital resource utilization while maintaining treatment adherence and patient safety.